These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37993788)

  • 1. Fading SARS-CoV-2 humoral VOC cross-reactivity and sustained cellular immunity in convalescent children and adolescents.
    Paniskaki K; Goretzki S; Anft M; Konik MJ; Lechtenberg K; Vogl M; Meister TL; Pfaender S; Zettler M; Jäger J; Dolff S; Westhoff TH; Rohn H; Felderhoff-Mueser U; Stervbo U; Witzke O; Dohna-Schwake C; Babel N
    BMC Infect Dis; 2023 Nov; 23(1):818. PubMed ID: 37993788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination.
    Paniskaki K; Konik MJ; Anft M; Meister TL; Marheinecke C; Pfaender S; Jäger J; Krawczyk A; Zettler M; Dolff S; Westhoff TH; Rohn H; Stervbo U; Witzke O; Babel N
    Front Immunol; 2022; 13():1031254. PubMed ID: 36389833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents.
    Tsang HW; Chua GT; To KKW; Wong JSC; Tu W; Kwok JSY; Wong WHS; Wang X; Zhang Y; Rosa Duque JS; Chan GCF; Chu WK; Pang CP; Tam PKH; Lau YL; Wong ICK; Leung WH; Yuen KY; Kwan MYW; Ip P
    Front Immunol; 2021; 12():797919. PubMed ID: 34975908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay.
    Cassaniti I; Percivalle E; Bergami F; Piralla A; Comolli G; Bruno R; Vecchia M; Sambo M; Colaneri M; Zuccaro V; Benazzo M; Robotti C; Calastri A; Maiorano E; Ferrari A; Cambiè G; Baldanti F
    Clin Microbiol Infect; 2021 Jul; 27(7):1029-1034. PubMed ID: 33813122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
    Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust and durable serological response following pediatric SARS-CoV-2 infection.
    Renk H; Dulovic A; Seidel A; Becker M; Fabricius D; Zernickel M; Junker D; Groß R; Müller J; Hilger A; Bode SFN; Fritsch L; Frieh P; Haddad A; Görne T; Remppis J; Ganzemueller T; Dietz A; Huzly D; Hengel H; Kaier K; Weber S; Jacobsen EM; Kaiser PD; Traenkle B; Rothbauer U; Stich M; Tönshoff B; Hoffmann GF; Müller B; Ludwig C; Jahrsdörfer B; Schrezenmeier H; Peter A; Hörber S; Iftner T; Münch J; Stamminger T; Groß HJ; Wolkewitz M; Engel C; Liu W; Rizzi M; Hahn BH; Henneke P; Franz AR; Debatin KM; Schneiderhan-Marra N; Janda A; Elling R
    Nat Commun; 2022 Jan; 13(1):128. PubMed ID: 35013206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children.
    Soto JA; Melo-González F; Gutierrez-Vera C; Schultz BM; Berríos-Rojas RV; Rivera-Pérez D; Piña-Iturbe A; Hoppe-Elsholz G; Duarte LF; Vázquez Y; Moreno-Tapia D; Ríos M; Palacios PA; Garcia-Betancourt R; Santibañez Á; Pacheco GA; Mendez C; Andrade CA; Silva PH; Diethelm-Varela B; Astudillo P; Calvo M; Cárdenas A; González M; Goldsack M; Gutiérrez V; Potin M; Schilling A; Tapia LI; Twele L; Villena R; Grifoni A; Sette A; Weiskopf D; Fasce RA; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Retamal-Díaz A; Muñoz-Jofré N; ; Meng X; Xin Q; Alarcón-Bustamante E; González-Aramundiz JV; Le Corre N; Álvarez-Figueroa MJ; González PA; Abarca K; Perret C; Carreño LJ; Bueno SM; Kalergis AM
    mBio; 2022 Dec; 13(6):e0131122. PubMed ID: 36383021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
    Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
    Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
    Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
    mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron.
    Sieber J; Mayer M; Schmidthaler K; Kopanja S; Camp JV; Popovitsch A; Dwivedi V; Hoz J; Schoof A; Weseslindtner L; Szépfalusi Z; Stiasny K; Aberle JH
    Front Immunol; 2022; 13():882456. PubMed ID: 35663948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects.
    Glück V; Tydykov L; Mader AL; Warda AS; Bertok M; Weidlich T; Gottwald C; Köstler J; Salzberger B; Wagner R; Koller M; Gessner A; Schmidt B; Glück T; Peterhoff D
    Infection; 2022 Dec; 50(6):1475-1481. PubMed ID: 35403960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression.
    Thieme CJ; Anft M; Paniskaki K; Blazquez-Navarro A; Doevelaar A; Seibert FS; Hoelzer B; Justine Konik M; Meister TL; Pfaender S; Steinmann E; Moritz Berger M; Brenner T; Kölsch U; Dolff S; Roch T; Witzke O; Schenker P; Viebahn R; Stervbo U; Westhoff TH; Babel N
    Transplantation; 2021 Oct; 105(10):2156-2164. PubMed ID: 33988334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral, Cellular and Cytokine Immune Responses Against SARS-CoV-2 Variants in COVID-19 Convalescent and Confirmed Patients With Different Disease Severities.
    Chiu CH; Chang YH; Chang FY; Hung YJ; Liao CL; Chiu KC; Tsai PL; Chang TW; Yen LC
    Front Cell Infect Microbiol; 2022; 12():862656. PubMed ID: 35656028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination.
    Harthaller T; Falkensammer B; Bante D; Huber M; Schmitt M; Benainouna H; Rössler A; Fleischer V; von Laer D; Kimpel J; Würzner R; Borena W
    Front Immunol; 2023; 14():1196988. PubMed ID: 37545492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
    Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
    Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.